Aptevo Therapeutics Inc. (APVO) Form 8-K — Aug 14, 2026
Aptevo Therapeutics furnished an 8-K on August 14, 2026 reporting second quarter 2026 results, led by updated RAINIER trial data for lead candidate mipletamig in frontline acute myeloid leukemia: an 87% clinical benefit rate and an 81% remission rate across 31 evaluable unfit patients treated in combination with venetoclax and azacitidine, with no cytokine release syndrome reported in frontline patients and six patients bridged to transplant. The company expects to complete dose optimization and select a Phase 2 dose by year-end 2026 ahead of a Phase 2 regulatory interaction in 1Q27.
Key figures
- Cash Position
- 9800000
- Grant amount
- 1500000
- Remission rate
- 81%
- Evaluable patients
- 31
- Clinical benefit rate
- 87%
- Niowave initial stake
- 7.9%
- Tp53 share of remissions
- 36%
- Radiopharm programs up to
- 3
- Mrd negative rate of CR CRi
- 55%
- Niowave max potential stake
- 19.99%
- Patients bridged to transplant
- 6
- Total treated patients experience
- 120+
Price after filing
Close on the filing date to close N calendar days later (from $2.94). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.